| 【Company Research】Anta Sports (2020 HK) - Staying cautious even after guidance cut |
| 【Company Research】WuXi AppTec (603259 CH) - Rising demand for small molecule D&M business |
| 【Company Research】Futu Holdings (FUTU US) - Marketing feedback: short-term views mixed; 3Q EPS upside to reinforce long-term convictions |
| 【Company Research】Jiangsu Hengli (601100 CH) - 3Q25 earnings growth accelerated to 31% YoY |
| 【Company Research】Xiaomi (1810 HK) - 3Q25 preview: expect another strong quarter on better EV business offsetting softer smartphone/IoT |
| 【Company Research】Topsports (6110 HK) - Guidance kept; prioritizing profit over sales |
| 【Company Research】Great Wall Motor (2333 HK/601633 CH) - Stronger FY26 sales outlook despite 3Q GPM miss |
| 【行业研究】中国医药 - 关注已授权药物的研发推进 |
| 【Company Research】Weibo (WB US) - 3Q25 preview: ad business under pressure amid headwinds in certain verticals |
| 【公司研究】巨子生物 (2367 HK) - 首款注射类医美产品获批，开启公司第二成长曲线 |
公司地址：香港中环花园道三号冠君大厦45-46楼
电话：（852）3900-0888 传真：（852）3761-8788
招银国际版权所有 Copyright © 2019-2026 CMB International Capital Corporation Limited. All rights reserved.
